Loading data for SANA — first visit, this takes a few seconds.

알림

Sana Biotechnology Inc. (SANA)

NasdaqGS: SANA · 실시간 가격 · USD

3.54

-0.13 (-3.54%)

종가 기준: Aug 14, 2026, 7:49 PM

-3.54% (1D)

데이터 없음

매수호가	n/a
시가총액	1.06B
매출 (ttm)	n/a
순이익 (ttm)	-211.82M
베타	2.10
EPS (ttm)	-0.75
P/E (ttm)	n/a
선행 P/E	-6.39
P/B (ttm)	8.02
P/S (ttm)	n/a
Earnings Date	Nov 5, 2026

매도호가	n/a
거래량	3,054,316
평균 거래량 (20일)	3,283,588
시가	3.64
전일 종가	3.67
일중 범위	3.37 - 3.64
52주 범위	2.61 - 6.55
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

SANA 소개

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical t...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 4, 2021

직원 수 142

상장 거래소 NasdaqGS

티커 SANA

웹사이트 https://www.sana.com

전체 기업 정보

재무 실적

2025년 Sana Biotechnology의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -244.17M로, -8.47% 감소했습니다.

재무제표

어닝 서프라이즈

Sana Biotechnology가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.13 예상치 하회 -0.01, 및 18.75% 전년 대비 성장.

다음 실적 발표

Sana Biotechnology Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Zacks

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

1개월 전 · Simply Wall St.

Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM

Sana Biotechnology (NasdaqGS:SANA) reported long term follow up data from an investigator sponsored study of its HIP modified islet cell therapy for type 1 diabetes. Results published in The New Engla...

1개월 전 · Zacks

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2개월 전 · Euronews

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.View on eu...

3개월 전 · Insider Monkey

Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes

Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the develo...

2 페이지 중 1

Sana Biotechnology Inc. (SANA)